Financial Contrast: Schrodinger (NASDAQ:SDGR) vs. SOPHiA GENETICS (NASDAQ:SOPH)

Schrodinger (NASDAQ:SDGR – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Profitability

This table compares Schrodinger and SOPHiA GENETICS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Schrodinger -22.02% -18.12% -9.07%
SOPHiA GENETICS -89.18% -128.69% -44.73%

Risk & Volatility

Schrodinger has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Earnings & Valuation

This table compares Schrodinger and SOPHiA GENETICS”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Schrodinger $269.20 million 8.10 -$103.26 million ($0.79) -37.38
SOPHiA GENETICS $90.97 million 7.57 -$79.00 million ($1.09) -7.53

SOPHiA GENETICS has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Schrodinger and SOPHiA GENETICS, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Schrodinger 1 3 4 0 2.38
SOPHiA GENETICS 1 1 3 0 2.40

Schrodinger presently has a consensus price target of $26.67, indicating a potential downside of 9.70%. SOPHiA GENETICS has a consensus price target of $10.00, indicating a potential upside of 21.80%. Given SOPHiA GENETICS’s stronger consensus rating and higher possible upside, analysts clearly believe SOPHiA GENETICS is more favorable than Schrodinger.

Insider and Institutional Ownership

79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Schrodinger beats SOPHiA GENETICS on 10 of the 14 factors compared between the two stocks.

About Schrodinger

(Get Free Report)

Schrödinger, Inc. develops computational software used to support drug discovery and materials research. Its platform applies physics-based modeling, computational chemistry and machine learning to help researchers analyze molecular properties and identify promising candidates. The company’s tools are used by pharmaceutical and biotechnology companies, academic institutions and other research organizations. Alongside software sales and subscriptions, Schrödinger works with partners on drug discovery programs and advances a portfolio of its own therapeutic candidates.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.

Receive News & Ratings for Schrodinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrodinger and related companies with MarketBeat.com's FREE daily email newsletter.